The GWAS confirms known associations, and hints at new ones. It suggests DLB is genetically distinct from AD or PD.
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
PET scans indicate no more AD pathology in PD-MCI than healthy controls, suggesting their cognitive decline results from other factors.
Ephemeral as they may be, these maligned peptides have become the targets of small-molecule and immunotherapies. Initial results of these efforts to catch and remove Aβ oligomers are trickling in.
Phase 1 trial tests the rejuvenating effects of young blood, while albumin replacement may offer its own benefits.
According to a press release by trial sponsor Ionis, therapy was well tolerated, but trial results have yet to be released.
In a Phase 2 trial in nursing home residents with Alzheimer’s, this new drug mitigated symptoms safely, without detriment to cognition.
Gradually raising the dose of this therapeutic antibody appears to ease the risk of brain inflammation.
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
In people who carry a repeat expansion in the C9ORF72 gene, gray and white matter are smaller and subtle impairments in cognition appear decades before symptom onset.
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials Automated CSF Tests: Check. Blood Tests: In the Works Cognitive Testing Is Getting Faster and Better Don’t Be an ...